Frontiers in Oncology | Hematologic Malignancies

Original Research

Published on 12 Apr 2024

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience

in Hematologic Malignancies

Francesco Angotzi
Federica Lessi
Matteo Leoncin
Carla Filì
Mauro Endri
Albana Lico
Andrea Visentin
Stefano Pravato
Anna Candoni
Livio Trentin

Frontiers in Oncology

doi 10.3389/fonc.2024.1370405

4,305 views
7 citations

Original Research

Published on 12 Apr 2024

Central venous catheters do not increase the hemorrhagic risk in acute promyelocytic leukemia patients during induction therapy

in Hematologic Malignancies

Manxiong Cao
Jiaqiong Hong
Dongqing Zhang
Feiheng Chen
Yongzhong Su

Frontiers in Oncology

doi 10.3389/fonc.2024.1332372

1,279 views
2 citations

Original Research

Published on 11 Apr 2024

Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm – collected cases from a single center and case reports

in Hematologic Malignancies

Philipp Faustmann
Jan C. Schroeder
Lucas Mix
Lennart Harland
Andreas Riedel
Wichard Vogel
Claudia Lengerke
Stefan Wirths

Frontiers in Oncology

doi 10.3389/fonc.2024.1384172

5,652 views
2 citations

Case Report

Published on 11 Apr 2024

Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review

in Hematologic Malignancies

Polina Bellman
Jesus D. Gonzalez-Lugo
Moazzam Shahzad
Muhammad Kashif Amin
Muhammad Fareed Khalid
Nahid Suleman
Nausheen Ahmed
Anurag K. Singh
Abdulraheem Yacoub
Da Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1383730

3,616 views
4 citations

Original Research

Published on 11 Apr 2024

Comparison of cytomorphology and histomorphology in myelodysplastic syndromes

in Hematologic Malignancies

Kathrin Nachtkamp
Corinna Strupp
Rosa Faoro
Norbert Gattermann
Sascha Dietrich
Ulrich Germing
Stefan Baldus

Frontiers in Oncology

doi 10.3389/fonc.2024.1359115

1,848 views
1 citation

Review

Published on 10 Apr 2024

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives

in Hematologic Malignancies

Ricardo D. Parrondo
Sikander Ailawadhi
Claudio Cerchione

Frontiers in Oncology

doi 10.3389/fonc.2024.1394048

11,537 views
12 citations

Review

Published on 09 Apr 2024

Targeted therapy for multiple myeloma: an overview on CD138-based strategies

in Hematologic Malignancies

Federico Riccardi
Carmela Tangredi
Michele Dal Bo
Giuseppe Toffoli

Frontiers in Oncology

doi 10.3389/fonc.2024.1370854

9,210 views
11 citations

Original Research

Published on 09 Apr 2024

Comparison of chemotherapy and chidamide combined with chemotherapy in patients with untreated angioimmunoblastic T-cell lymphoma

in Hematologic Malignancies

Simeng Gu
Xin Wang
Jingqiu Zhou
Shanshan Du
Ting Niu

Frontiers in Oncology

doi 10.3389/fonc.2024.1373127

1,997 views

Systematic Review

Published on 08 Apr 2024

Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis

in Hematologic Malignancies

Han Xu
Chaoyang Guan
Peipei Xu
Dongming Zhou
Yong Xu
Bing Chen
Hua Bai

Frontiers in Oncology

doi 10.3389/fonc.2024.1355643

5,066 views
7 citations

Brief Research Report

Published on 08 Apr 2024

Co-operation of MCL-1 and BCL-XL anti-apoptotic proteins in stromal protection of MM cells from carfilzomib mediated cytotoxicity

in Hematologic Malignancies

Daria Galas-Filipowicz
Selina J. Chavda
Jia-Nan Gong
David C. S. Huang
Asim Khwaja
Kwee Yong

Frontiers in Oncology

doi 10.3389/fonc.2024.1394393

3,169 views
4 citations

Original Research

Published on 08 Apr 2024

Genetic prediction of causal association between serum bilirubin and hematologic malignancies: a two-sample Mendelian randomized and bioinformatics study

in Hematologic Malignancies

Lihua Lu
Luting Luo
Xiang Li
Wanying Liu
Boheng Wu
Qing Cai
Jiazheng Li
Yan Huang
Yanxin Chen
Yongzhi Zheng

Frontiers in Oncology

doi 10.3389/fonc.2024.1364834

2,844 views
1 citation

Mini Review

Published on 04 Apr 2024

Competing risks data in clinical oncology

in Hematologic Malignancies

Haesook Teresa Kim

Frontiers in Oncology

doi 10.3389/fonc.2024.1360266

3,548 views
4 citations

Original Research

Published on 03 Apr 2024

IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia

in Hematologic Malignancies

Joaquin Garcia-Solorio
Juan Carlos Núñez-Enriquez
Marco Jiménez-Olivares
Janet Flores-Lujano
Fernanda Flores-Espino
Carolina Molina-Garay
Alejandra Cervera
Diana Casique-Aguirre
José Gabriel Peñaloza-Gonzalez
Ma. Del Rocío Baños-Lara

Frontiers in Oncology

doi 10.3389/fonc.2024.1337954

7,133 views
4 citations

Mini Review

Published on 03 Apr 2024

Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications

in Hematologic Malignancies

Mariusz A. Wasik
Patricia M. Kim
Reza Nejati

Frontiers in Oncology

doi 10.3389/fonc.2024.1383741

2,125 views
2 citations

Original Research

Published on 03 Apr 2024

Analysis of the treatment and prognosis of 266 cases of extranodal natural killer/T-cell lymphoma, nasal type in a single medical center

in Hematologic Malignancies

Lei Yang
Liqiang Wei
Xin Li
Jia Cong
Jin Ye
Na Yao
Jing Yang
Liang Wang
Jingwen Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1388564

2,233 views

Review

Published on 02 Apr 2024

Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches

in Hematologic Malignancies

Claudia Bozzini
Fabiana Busti
Giacomo Marchi
Alice Vianello
Claudio Cerchione
Giovanni Martinelli
Domenico Girelli

Frontiers in Oncology

doi 10.3389/fonc.2024.1380358

9,732 views
23 citations

Original Research

Published on 28 Mar 2024

CD20+ T cells in monoclonal B cell lymphocytosis and chronic lymphocytic leukemia: frequency, phenotype and association with disease progression

in Hematologic Malignancies

Cristiana Rodrigues
Paula Laranjeira
Aryane Pinho
Isabel Silva
Sandra Silva
Margarida Coucelo
Ana Catarina Oliveira
Ana Teresa Simões
Inês Damásio
Helena Matos Silva

Frontiers in Oncology

doi 10.3389/fonc.2024.1380648

4,411 views
4 citations

Review

Published on 27 Mar 2024

Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy

in Hematologic Malignancies

Charlotte F. M. Hughes
Gunjan L. Shah
Barry A. Paul

Frontiers in Oncology

doi 10.3389/fonc.2024.1373548

6,214 views
1 citation

Systematic Review

Published on 26 Mar 2024

Venetoclax combined chemotherapy versus chemotherapy alone for acute myeloid leukemia: a systematic review and meta-analysis

in Hematologic Malignancies

Jingkui Zhu
Jixin Fan
Tiantian Xie
Haiqiu Zhao
Runqing Lu
Yinyin Zhang
Yingmei Li
Xinsheng Xie
Dingming Wan
Zhongxing Jiang

Frontiers in Oncology

doi 10.3389/fonc.2024.1361988

3,963 views
1 citation

Original Research

Published on 26 Mar 2024

Decreasing the steroid rapidly may help to improve the clinical outcomes of patients with intestinal steroid-refractory acute graft-versus-host disease receiving basiliximab treatment

in Hematologic Malignancies

Cong Cheng
Dao-Xing Deng
Xiao-Hui Zhang
Lan-Ping Xu
Yu Wang
Chen-Hua Yan
Huan Chen
Yu-Hong Chen
Wei Han
Feng-Rong Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1390438

1,868 views

Case Report

Published on 25 Mar 2024

A case report of atypical chronic myeloid leukemia with complete hematological and major molecular response to Venetoclax/Azacitidine treatment

in Hematologic Malignancies

Hongxia Chen
Ning Wang
Yin Li
Xiaohong Xie
Yi Yang

Frontiers in Oncology

doi 10.3389/fonc.2024.1327834

2,438 views
1 citation

Review

Published on 22 Mar 2024

Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma

in Hematologic Malignancies

Catarina Geraldes
Adriana Roque
Ana Bela Sarmento-Ribeiro
Manuel Neves
Alina Ionita
Rita Gerivaz
Ana Tomé
Sofia Afonso
Maria Pedro Silveira
Patrícia Sousa

Frontiers in Oncology

doi 10.3389/fonc.2024.1282300

7,147 views
8 citations

Original Research

Published on 22 Mar 2024

TNF-α is a predictive marker in distinguishing myeloproliferative neoplasm and idiopathic erythrocytosis/thrombocytosis: development and validation of a non-invasive diagnostic model

in Hematologic Malignancies

Zhenhao Wang
Yu Mei
Zhuming Yang
Qiang Gao
Hao Xu
Zhiqiang Han
Zhenya Hong

Frontiers in Oncology

doi 10.3389/fonc.2024.1369346

2,386 views

Original Research

Published on 21 Mar 2024

CD7-positive leukemic blasts with DNMT3A mutations predict poor prognosis in patients with acute myeloid leukemia

in Hematologic Malignancies

Yanliang Bai
Xiaobai Sun
Mengyi Li
Xiaona Niu
Weijie Cao
Junwei Niu
Xingjun Xiao
Yuqing Chen
Kai Sun

Frontiers in Oncology

doi 10.3389/fonc.2024.1342998

3,052 views
1 citation

2,009 articles

articles

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience

Central venous catheters do not increase the hemorrhagic risk in acute promyelocytic leukemia patients during induction therapy

Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm – collected cases from a single center and case reports

Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review

Comparison of cytomorphology and histomorphology in myelodysplastic syndromes

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives

Targeted therapy for multiple myeloma: an overview on CD138-based strategies

Comparison of chemotherapy and chidamide combined with chemotherapy in patients with untreated angioimmunoblastic T-cell lymphoma

Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis

Co-operation of MCL-1 and BCL-XL anti-apoptotic proteins in stromal protection of MM cells from carfilzomib mediated cytotoxicity

Genetic prediction of causal association between serum bilirubin and hematologic malignancies: a two-sample Mendelian randomized and bioinformatics study

Competing risks data in clinical oncology

IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia

Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications

Analysis of the treatment and prognosis of 266 cases of extranodal natural killer/T-cell lymphoma, nasal type in a single medical center

Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches

CD20+ T cells in monoclonal B cell lymphocytosis and chronic lymphocytic leukemia: frequency, phenotype and association with disease progression

Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy

Venetoclax combined chemotherapy versus chemotherapy alone for acute myeloid leukemia: a systematic review and meta-analysis

Decreasing the steroid rapidly may help to improve the clinical outcomes of patients with intestinal steroid-refractory acute graft-versus-host disease receiving basiliximab treatment

A case report of atypical chronic myeloid leukemia with complete hematological and major molecular response to Venetoclax/Azacitidine treatment

Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma

TNF-α is a predictive marker in distinguishing myeloproliferative neoplasm and idiopathic erythrocytosis/thrombocytosis: development and validation of a non-invasive diagnostic model

CD7-positive leukemic blasts with DNMT3A mutations predict poor prognosis in patients with acute myeloid leukemia